Johnson & Johnson filings document the regulatory record for a New Jersey healthcare company with Innovative Medicine and MedTech operations. Recent 8-K reports cover sales and earnings releases, dividend actions, annual meeting voting results and other material corporate events.
The company’s proxy materials describe board elections, executive compensation votes and shareholder governance matters. Its exchange-registered securities include JNJ common stock and multiple NYSE-listed notes with maturities extending across the company’s long-term debt profile.
John G. Morikis submitted an initial Form 3 disclosing beneficial ownership in Johnson & Johnson (JNJ). The filing reports direct ownership of 598.51 shares and indicates Mr. Morikis serves as a director of the issuer. The event requiring the statement is dated 09/08/2025 and the Form 3 was signed by an attorney-in-fact on 09/15/2025. The filing is an initial ownership disclosure under Section 16.
Marillyn A. Hewson, a director of Johnson & Johnson (JNJ), acquired 280.788 Deferred Share Units (DSUs) on 09/09/2025 under the company's Amended and Restated Deferred Fee Plan for Directors. The DSUs were recorded at a per-unit value of $178.07 and will be settled in cash upon termination of the reporter's directorship. The reported DSUs include accrued dividend equivalent rights tied to the issuer's quarterly dividend. Following the transaction the reporting person’s total DSU exposure is shown as 13,816.8727 units.
Daniel E. Pinto, a director of Johnson & Johnson (JNJ), acquired 175.493 Deferred Share Units (DSUs) on 09/09/2025 under the company's Amended and Restated Deferred Fee Plan for Directors. Each DSU equals the fair market value of one share of JNJ common stock at the business day before settlement and will be settled in cash when Mr. Pinto's directorship ends. The reported per-unit price for the DSUs is $178.07, resulting in 175.493 units held directly after the transaction. The Form 4 was filed and signed on 09/11/2025.
Johnson & Johnson director Eugene A. Woods reported an acquisition of 210.591 Deferred Share Units (DSUs) on 09/09/2025. The filing lists an acquisition price of $178.07 per unit and shows the reporting person beneficially owned 4,841.3962 DSUs following the transaction. The DSUs were granted under the issuer's Amended and Restated Deferred Fee Plan for Directors and were received in deferral of a cash retainer. The DSUs are payable in cash upon termination of the director's service and each DSU represents the fair market value of one share at settlement. The filing was signed by an attorney-in-fact on behalf of Mr. Woods on 09/11/2025.
Jennifer L. Taubert, Executive Vice President, Worldwide Chairman - Innovative Medicine at Johnson & Johnson (JNJ), reported option exercise and an immediate sale on 09/04/2025. She exercised 56,471 employee stock options with an exercise price of $101.87 per share, producing 56,471 common shares. Those same 56,471 shares were sold the same day in multiple trades at a weighted average sale price of $177.806 per share. The Form 4 shows beneficial ownership figures of 234,484 shares following the acquisition line and 178,013 shares following the sale line. The filing is signed by an attorney-in-fact on 09/05/2025.
Form 144 notice for proposed sale of securities. The filing reports an intended sale of 56,471 shares of common stock on 09/04/2025 on the NYSE, with an aggregate market value of $10,040,904.33. The shares represent part of total outstanding common shares of 2,408,338,872. The securities were listed as acquired on 09/04/2025 by exercise of an option originally granted on 02/08/2016, and the payment method is cash. The broker named is Fidelity Brokerage Services LLC, 900 Salem Street, Smithfield RI 02917. The filing contains no reportable sales in the prior three months and does not provide the issuer's full identifying details in the visible fields.
Insider transaction summary for Johnson & Johnson (JNJ): Elizabeth Forminard, Executive VP and General Counsel, reported option-related activity on 08/29/2025. She exercised 11,521 employee stock options with an exercise price of $115.67, acquiring 11,521 shares at that price. Following the exercise, she sold 9,570 shares at $177.20, leaving her beneficial ownership at 12,853 shares of common stock. The options exercised were originally granted on 02/13/2020 and vested to be exercisable on the third anniversary of the grant; their expiration date is 02/13/2027. The Form 4 was signed by an attorney-in-fact on 09/03/2025.
Form 144 notice for Johnson & Johnson (JNJ) reports a proposed sale of 9,570 shares of Common stock through Fidelity Brokerage Services with an aggregate market value of $1,695,805.91, to be sold approximately on 08/29/2025 on the NYSE. The filing lists total shares outstanding as 2,408,338,872.
The filer indicates the shares were acquired via an option (granted 02/13/2017) and the acquisition and payment date is recorded as 08/29/2025 with payment in cash. No other securities were reported sold in the past three months and the form contains the standard certification regarding lack of undisclosed material information.
Joaquin Duato, CEO and Chairman of Johnson & Johnson (JNJ), reported transactions on Form 4 dated 08/22/2025 showing the exercise and sale of company shares. On 08/22/2025 he exercised 125,824 employee stock options at an exercise price of $101.87 per share, and contemporaneously sold 125,824 shares at a weighted average sale price of $179.2079. After these transactions the filing shows 275,967 shares beneficially owned directly. The report also discloses 401,791 shares held directly following another acquisition entry and 130,852 shares held indirectly by spouse and 974 shares indirectly via a 401(k) plan as of the plan reporting date.
The Form 4 was signed by an attorney-in-fact on 08/25/2025 and includes an explanation that the sale prices reflect multiple trades between $178.985 and $179.37 and that dividend reinvestment figures are as of 07/31/2025. The filing documents a routine insider option exercise and sale rather than disclosure of new compensation terms.
Johnson & Johnson (JNJ) filed a Form 144 reporting a proposed sale of 125,824 common shares through Fidelity Brokerage Services with an aggregate market value of $22,652,723.84. The filing states the shares are to be sold on or about 08/22/2025 and that the shares were acquired via an option granted on 02/08/2016, with payment to be cash at sale.
The filer certifies there is no undisclosed material information and indicates no other securities of the issuer were sold by the same person in the past three months. The disclosure documents a sizable, rule-compliant planned insider sale routed through a broker on the NYSE.